The FDA granted priority review to tebentafusp for treatment of adults with HLA-A*02:01-positive metastatic uveal melanoma.
Uveal melanoma is an aggressive form of cancer for which treatment options are limited.
Tebentafusp (Immunocore Holdings) is a novel bispecific protein comprised of a soluble T-cell receptor fused to an anti-CD3 immune-effector function.
The agent targets gp100, a lineage antigen expressed in melanocytes and melanoma, according to an Immunocore-issued press release.
The FDA based priority review on findings from the randomized phase 3 IMCgp100-202 trial, which compared